There are two areas in which glycobiology has been very successful: technology development and disease correlation. Through efforts exemplified by the CFG, major strides in mass spectroscopy and the creation of novel technologies for probing glycan-protein interactions (e.g. glycan microarrays) have been seen. Likewise, the success of the Programs of Excellence in Glycoscience and those of us focused on disease have also established robust correlations between susceptibility of disease and glycosylation alterations, change in the glycome associated with disease (e.g., cancer, autoimmunity, asthma, inflammation), and others. Too little, however, has been accomplished in determining the underlying molecular mechanisms for these correlations.